Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.